2006 · RCT
Zarate et al. 2006 - replication in TRD
A randomized trial of an NMDA antagonist in treatment-resistant major depression
Medically reviewed by: Pending medical review(draft)Last updated: June 4, 2026Evidence: Zarate CA Jr et al.. Archives of General Psychiatry, 2006.
Population
18 patients with treatment-resistant depression
Intervention
Single IV ketamine infusion (0.5 mg/kg)
Comparator
Saline placebo, crossover design
Primary outcome
HAM-D score over 7 days
Key findings
- 71% of patients met response criteria within 24 hours
- 35% maintained response at 7 days
- Established TRD as a target population
Limitations
- Small sample
- Single dose
- Short follow-up
Educational use only. The content on this page is provided for general educational purposes and does not constitute medical advice, diagnosis, or treatment. Ketamine and related therapies carry risks and are appropriate only under qualified medical supervision. Always consult a licensed healthcare professional about your individual situation. Information may change as research evolves.